Skip to main content

Articles

336 result(s) for 'ctla 4' within BMC Cancer

Page 3 of 7

  1. Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents. The aim of this retrospective study was to assess the ...

    Authors: Song Chen, Bo Xu, Zhiqiang Wu, Pengfei Wang, Weiguang Yu, Zhiyong Liu, Xiaoyong Huang, Yanqing Wu, Tengfei Li and Wenbo Guo
    Citation: BMC Cancer 2021 21:1126
    Content type: Research Published on:

  2. Sarcomas constitute a heterogeneous group of tumors with different clinical behaviors and variable responses to systemic therapies. Recent immunotherapy studies with PD1 inhibitors (PD1i) show promising result...

    Authors: Dionisia Quiroga, David A. Liebner, Jennifer S. Philippon, Sarah Hoffman, Yubo Tan, James L. Chen, Scott Lenobel, Paul E. Wakely Jr, Raphael Pollock and Gabriel Tinoco
    Citation: BMC Cancer 2020 20:527
    Content type: Research article Published on:

  3. Pazopanib, a multitargeted tyrosine kinase inhibitor, is recommended as the standard treatment for refractory soft tissue sarcoma (STS). However, there are comparatively few molecular determinants for predicti...

    Authors: Sang Kyum Kim, Jee Hung Kim, Seung Hyun Kim, Young Han Lee, Jung Woo Han, Wooyeol Baek, Ha Young Woo, Min Kyung Jeon and Hyo Song Kim
    Citation: BMC Cancer 2021 21:336
    Content type: Research article Published on:

  4. Despite the wide-spread use of immune checkpoint inhibitors (ICIs) in cancer chemotherapy, reports on patients developing acquired resistance (AR) to ICI therapy are scarce. Therefore, we first investigated th...

    Authors: Kazutaka Hosoya, Daichi Fujimoto, Takeshi Morimoto, Toru Kumagai, Akihiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Tadashi Ishida, Hirotaka Matsumoto, Katsuya Hirano, Ryota Kominami, Keisuke Tomii, Hidekazu Suzuki, Tomonori Hirashima, Satoshi Tanaka, Junji Uchida…
    Citation: BMC Cancer 2021 21:346
    Content type: Research article Published on:

  5. Pucotenlimab is a novel recombinant humanized anti-PD-1 (Programmed death-1) monoclonal antibody, which belongs to the human IgG4/kappa subtype, and can selectively block the binding of PD-1 with its ligands P...

    Authors: Chuanliang Cui, Yu Chen, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Xuan Wang, Taiyang Ma, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng…
    Citation: BMC Cancer 2023 23:121
    Content type: Research Published on:

  6. Activated Cdc42-associated kinase 1 (ACK1), a kind of tyrosine kinase, is considered to be an oncogene in many cancers, and it is likely to become a potential target for cancer treatment. We found that the exp...

    Authors: Defeng Kong, Guoliang Li, Zhenrong Yang, Shujun Cheng, Wen Zhang, Lin Feng and Kaitai Zhang
    Citation: BMC Cancer 2022 22:84
    Content type: Research Published on:

  7. Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that converts tryptophan to kynurenine. IDO1 expression is found not only in tumor cells but also in immune cells and is associated with tumor proliferation an...

    Authors: Hiroaki Nozawa, Tetsuro Taira, Hirofumi Sonoda, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Yuzo Nagai, Shinya Abe and Soichiro Ishihara
    Citation: BMC Cancer 2023 23:62
    Content type: Research Published on:

  9. Well-designed clinical trials are of great importance in validating novel treatments and ensuring an evidence-based approach for sarcoma. This study aimed to provide a comprehensive landscape of the characteri...

    Authors: Y Que, W Xiao, BS Xu, XZ Wen, DS Weng and X Zhang
    Citation: BMC Cancer 2018 18:1251
    Content type: Research article Published on:

  10. Antibodies and derivative drugs targeting immune checkpoints have been approved for the treatment of several malignancies, but there are fewer responses in patients with pancreatic cancer. Here, we designed a ...

    Authors: Shuai Hao, Shuyi Xu, Liangzhu Li, Yaxian Li, Meiqi Zhao, Junsheng Chen, Shunying Zhu, Yueqing Xie, Hua Jiang, Jianwei Zhu and Mingyuan Wu
    Citation: BMC Cancer 2022 22:1092
    Content type: Research Published on:

  11. The aim of this study was to determine the safety and efficacy of fractionated stereotactic radiotherapy (SRT) in combination with systemic therapies (ST) for brain metastases (BM).

    Authors: Morgan Guénolé, François Lucia, Vincent Bourbonne, Gurvan Dissaux, Emmanuelle Reygagne, Gaëlle Goasduff, Olivier Pradier and Ulrike Schick
    Citation: BMC Cancer 2020 20:991
    Content type: Research article Published on:

  13. Gastric cancer (GC) remains a predominant form of malignant tumor globally, necessitating innovative non-surgical therapeutic approaches. This investigation aimed to delineate the expression landscape of macro...

    Authors: Zhijun Hong, Peizhen Wen, Kang Wang, Xujin Wei, Wen Xie, Shihao Rao, Xin Chen, Jingjing Hou and Huiqin Zhuo
    Citation: BMC Cancer 2024 24:141
    Content type: Research Published on:

  14. CD276 (also known as B7-H3) is one of the most important immune checkpoints of the CD28 and B7 superfamily, and its abnormal expression is closely associated with various types of cancer. It has been shown that C...

    Authors: Lirui Dai, Xuyang Guo, Zhe Xing, Yiran Tao, Wulong Liang, Zimin Shi, Weihua Hu, Shaolong Zhou and Xinjun Wang
    Citation: BMC Cancer 2023 23:102
    Content type: Research Published on:

  15. Hepatocellular carcinoma (HCC) is considered one of the most common cancers, characterized by low early detection and high mortality rates, and is a global health challenge. Immunogenic cell death (ICD) is def...

    Authors: Cai-Feng Lin, Zhi-Wen Chen, Feng-Ping Kang, Jian-Fei Hu, Long Huang, Cheng-Yu Liao, Jian-Lin Lai, Yi Huang, Zu-Wei Wang, Yi-Feng Tian and Shi Chen
    Citation: BMC Cancer 2023 23:522
    Content type: Research Published on:

  16. Clear cell renal cell carcinoma (ccRCC) is common in urinary system tumors. Cuproptosis is a non-apoptotic cell death pathway. Copper binds to fatty acylated mitochondrial proteins and activates various forms ...

    Authors: Junlin Shen, Linhui Wang and Jianbin Bi
    Citation: BMC Cancer 2023 23:160
    Content type: Research Published on:

  18. Cancer stemness has been proven to affect tumorigenesis, metastasis, and drug resistance in various cancers, including lung squamous cell carcinoma (LUSC). We intended to develop a clinically applicable stemne...

    Authors: Jinzhi Lai, Xinyi Lin, Huangna Zheng, Bilan Xie and Deqiang Fu
    Citation: BMC Cancer 2023 23:525
    Content type: Research Published on:

  19. Melanoma-intrinsic activated β-catenin pathway, the product of the catenin beta 1 (CTNNB1)...gene, has been associated with low/absent tumor-infiltrating lymphocytes, accelerated tumor growth, metastases developm...

    Authors: Georgia Sofia Karachaliou, Rached Alkallas, Sarah B. Carroll, Chongshan Caressi, Danny Zakria, Nirali M. Patel, Dimitri G. Trembath, Jennifer A. Ezzell, Guillaume J. Pegna, Paul B. Googe, Jonathan P. Galeotti, Fatih Ayvali, Frances A. Collichio, Carrie B. Lee, David W. Ollila, Margaret L. Gulley…
    Citation: BMC Cancer 2022 22:38
    Content type: Research Published on:

  20. A malignancy of the liver, hepatocellular carcinoma (HCC) is among the most common and second-leading causes of cancer-related deaths worldwide. A reliable prognosis model for guidance in choosing HCC therapie...

    Authors: Chunting Zeng, Linmeng Zhang, Chanhua Luo, Chen Yang, Xiaowen Huang, Linfeng Fan, Jiarong Li, Fengsheng Chen and Zelong Luo
    Citation: BMC Cancer 2022 22:613
    Content type: Research article Published on:

  21. Immune checkpoint inhibitors (ICIs) reported remarkable achievements in several solid tumours. However, in metastatic colorectal cancer (mCRC) promising results are limited to patients with deficient mismatch ...

    Authors: Carlotta Antoniotti, Beatrice Borelli, Daniele Rossini, Filippo Pietrantonio, Federica Morano, Lisa Salvatore, Sara Lonardi, Federica Marmorino, Stefano Tamberi, Salvatore Corallo, Giampaolo Tortora, Francesca Bergamo, Di Stefano Brunella, Alessandra Boccaccino, Elisa Grassi, Patrizia Racca…
    Citation: BMC Cancer 2020 20:683
    Content type: Study protocol Published on:

  22. CD73 is one of the critical component in the formation of immunosuppressive microenvironment in cancers. We aimed to provide an overview of the current status of CD73 expression and its relationship with clini...

    Authors: Tao Jiang, Xiaofeng Xu, Meng Qiao, Xuefei Li, Chao Zhao, Fei Zhou, Guanghui Gao, Fengying Wu, Xiaoxia Chen, Chunxia Su, Shengxiang Ren, Changyun Zhai and Caicun Zhou
    Citation: BMC Cancer 2018 18:267
    Content type: Research article Published on:

  23. Immunotherapy has become a new therapy for advanced hepatocellular carcinoma (HCC); however, its treatment results are considerably different. CD4+ T cells (CD4+) are the key to immunotherapy, but patients wit...

    Authors: Yong Zhao, Ling Xiang Kong, Feng Shi Feng, Jiayin Yang and Guo Wei
    Citation: BMC Cancer 2022 22:311
    Content type: Research Published on:

  25. Leptomeningeal metastasis of melanoma is a devastating complication with a grave prognosis, and there are no known effective standard treatments. Although selective BRAF inhibitors have demonstrated a signific...

    Authors: Dae Won Kim, Edelyn Barcena, Urvi N Mehta, Michelle L Rohlfs, Ashok J Kumar, Marta Penas-Prado and Kevin B Kim
    Citation: BMC Cancer 2015 15:400
    Content type: Case report Published on:

  26. Patients from non-small cell lung cancer (NSCLC) controlled clinical trials do not always reflect real-world heterogeneous patient populations. We designed a study to describe the real-world patient characteri...

    Authors: Hozefa A. Divan, Marisa A. Bittoni, Ashok Krishna and David P. Carbone
    Citation: BMC Cancer 2024 24:424
    Content type: Research Published on:

  27. In patients with previously treated RAS-mutated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), a multicenter open-label phase 1b/2 trial was conducted to define the safety and efficacy of the ME...

    Authors: Elena Elez, Antonio Cubillo, Pilar Garcia Alfonso, Mark R. Middleton, Ian Chau, Baha Alkuzweny, Ann Alcasid, Xiaosong Zhang and Eric Van Cutsem
    Citation: BMC Cancer 2024 24:446
    Content type: Research Published on:

  28. The optimal duration of anti-PD-1 for cancer therapy has not been tested, especially when using combination therapy. Epidermal growth factor receptor (EGFR) pathway blocker was the top compound that enhanced T...

    Authors: Hsiang-Fong Kao, Huai-Cheng Huang, Bin-Chi Liao and Ruey-Long Hong
    Citation: BMC Cancer 2022 22:1228
    Content type: Research Published on:

  30. FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic col...

    Authors: Angela Damato, Francesco Iachetta, Lorenzo Antonuzzo, Guglielmo Nasti, Francesca Bergamo, Roberto Bordonaro, Evaristo Maiello, Alberto Zaniboni, Giuseppe Tonini, Alessandra Romagnani, Annalisa Berselli, Nicola Normanno and Carmine Pinto
    Citation: BMC Cancer 2020 20:822
    Content type: Study protocol Published on:

  31. Anti-tumor effects of radiation therapy (RT) largely depend on host immune function. Adenosine with its strong immunosuppressive properties is an important immune checkpoint molecule.

    Authors: Hidenori Tsukui, Hisanaga Horie, Koji Koinuma, Hideyuki Ohzawa, Yasunaru Sakuma, Yoshinori Hosoya, Hironori Yamaguchi, Kotaro Yoshimura, Alan Kawarai Lefor, Naohiro Sata and Joji Kitayama
    Citation: BMC Cancer 2020 20:411
    Content type: Research article Published on:

  32. Previous study has shown that chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family member 4 (CMTM4) can bind and maintain programmed cell death ligand 1 (PD-L1) expression to promote...

    Authors: Shengkui Tan, Xuefeng Guo, Chunhua Bei, Huixia Zhang, Di Li, Xiaonian Zhu and Hongzhuan Tan
    Citation: BMC Cancer 2022 22:905
    Content type: Research article Published on:

  33. While immune-checkpoint inhibitors (ICIs) have transformed the field of oncology for advanced-stage cancers, they can lead to serious immune toxicities. Several systematic reviews have evaluated the risk of im...

    Authors: Zahra Karimian, Sandra Mavoungou, Joe-Elie Salem, Florence Tubach and Agnès Dechartres
    Citation: BMC Cancer 2020 20:1128
    Content type: Research article Published on:

  34. The interferon-induced protein known as guanylate-binding protein 2 (GBP2) has been linked to multiple different cancer types as an oncogenic gene. Although the role of GBP2 in cancer has been preliminarily ex...

    Authors: Yunfei Wang, Jiadong Pan, Fangmei An, Ke Chen, Jiawei Chen, He Nie, Yanping Zhu, Zhengtao Qian and Qiang Zhan
    Citation: BMC Cancer 2023 23:925
    Content type: Research Published on:

  35. Tumor microenvironment (TME) is of great importance to regulate the initiation and advance of cancer. The immune infiltration patterns of TME have been considered to impact the prognosis and immunotherapy sens...

    Authors: Yinghe Ding, Ling Chu, Qingtai Cao, Hanyu Lei, Xinyu Li and Quan Zhuang
    Citation: BMC Cancer 2023 23:45
    Content type: Research Published on:

  36. Gliomas are the most common malignant brain tumors, with powerful invasiveness and an undesirable prognosis. Actin related protein 2/3 complex subunit 5 (ARPC5) encodes a component of the Arp2/3 protein comple...

    Authors: Yue Ming, Chunyuan Luo, Beihong Ji and Jian Cheng
    Citation: BMC Cancer 2023 23:937
    Content type: Research Published on:

  37. N6-methyladenosine (m6A) modification and long non-coding RNAs (lncRNAs) play pivotal roles in gastric cancer (GC) progression. The emergence of immunotherapy in GC has created a paradigm shift in the approach...

    Authors: Yi Wang, Gui-Qi Zhu, Di Tian, Chang-Wu Zhou, Na Li, Ying Feng and Meng-Su Zeng
    Citation: BMC Cancer 2022 22:316
    Content type: Research Published on:

  38. Patients with locally advanced bladder cancer (cT3/4 cN0/N+ cM0) have a poor prognosis despite radical surgical therapy and perioperative chemotherapy. Preliminary data suggest that the combination of radiatio...

    Authors: Sebastian C. Schmid, Florestan J. Koll, Claus Rödel, Philipp Maisch, Andreas Sauter, Franziska Beckert, Anna Seitz, Hubert Kübler, Michael Flentje, Felix Chun, Stephanie E. Combs, Kilian Schiller, Jürgen E. Gschwend and Margitta Retz
    Citation: BMC Cancer 2020 20:8
    Content type: Study protocol Published on:

  39. Patients with activating epidermal growth factor receptor (EGFR) mutations are highly responsive to EGFR-tyrosine kinase inhibitors (TKIs). However, it has been reported that approximately 15–30% of patients trea...

    Authors: Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Masafumi Takeshita, Takayuki Suetsugu, Keisuke Kirita, Noriyuki Ebi, Osamu Hataji, Satoru Miura, Kenji Chibana, Isamu Okamoto, Kenichi Yoshimura, Kazuhiko Nakagawa, Nobuyuki Yamamoto and Kenji Sugio
    Citation: BMC Cancer 2020 20:370
    Content type: Study protocol Published on:

  40. Immunotherapy is a vital component in cancer treatment. However, due to the complex genetic bases of cancer, a clear prediction index for efficacy has not been established. Tumor mutation burden (TMB) is one o...

    Authors: Liwei Wang, Fu Chen, Rui Liu, Lei Shi, Guosheng Zhao and Zhengjian Yan
    Citation: BMC Cancer 2021 21:379
    Content type: Research article Published on:

  41. Immunotherapy has emerged as a robust clinical strategy for cancer treatment. PD1/PD-L1 inhibitors have been used as second-line therapy for urothelial carcinoma due to the high tumor mutational burden. Despit...

    Authors: Qing Zhang, Wenlong Zhang, Tingsheng Lin, Wenfeng Lu, Xin He, Yuanzhen Ding, Wei Chen, Wenli Diao, Meng Ding, Pingping Shen and Hongqian Guo
    Citation: BMC Cancer 2022 22:677
    Content type: Research Published on:

  42. The specific differentiation potential, unlimited proliferation, and self-renewal capacity of cancer stem cells (CSCs) are closely related to the occurrence, recurrence, and drug resistance of hepatocellular c...

    Authors: Genhao Zhang, Kai Zhang, Yanteng Zhao, Qiankun Yang and Xianping Lv
    Citation: BMC Cancer 2022 22:1103
    Content type: Research Published on:

  43. There is now a renewed interest in cancer vaccines. Patients responding to immune checkpoint blockade usually bear tumors that are heavily infiltrated by T cells and express a high load of neoantigens, indicat...

    Authors: Sheeba K. Thomas, Soung-chul Cha, D. Lynne Smith, Kun Hwa Kim, Sapna R. Parshottam, Sheetal Rao, Michael Popescu, Vincent Y. Lee, Sattva S. Neelapu and Larry W. Kwak
    Citation: BMC Cancer 2018 18:187
    Content type: Study protocol Published on:

  44. Gastric cancer (GC) is one of the most prevalent malignant tumors worldwide and is associated with high morbidity and mortality rates. However, the specific biomarkers used to predict the postoperative prognos...

    Authors: Shuchang Wang, Weifeng Zhang, Xinrui Wu, Zhu Zhu, Yuanbiao Chen, Wangrui Liu, Junnfei Xu, Li Chen and Chun Zhuang
    Citation: BMC Cancer 2024 24:570
    Content type: Research Published on:

  46. S100A16 protein belongs to the S100 family of calcium-binding proteins, which is widely distributed in human tissues and highly conserved. S100 calcium-binding proteins possess broad biological functions, such...

    Authors: Haibin Zhang, Yongxiu Yang, Wenhu Xing, Yufeng Li and Shan Zhang
    Citation: BMC Cancer 2023 23:1124
    Content type: Research Published on:

  47. Tumor protein p53 (TP53) is the most frequently mutated gene in head and neck squamous cell carcinoma (HNSC), and TP53 mutations are associated with inhibited immune signatures and poor prognosis. We established ...

    Authors: Congyu Shi, Shan Liu, Xudong Tian, Xiaoyi Wang and Pan Gao
    Citation: BMC Cancer 2021 21:1035
    Content type: Research Published on:

  48. Although numerous studies have reported the prognostic value of the lung immune prognostic index (LIPI) in non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs), the prog...

    Authors: Yusheng Guo, Yao Pan, Jiayu Wan, Bingxin Gong, Yi Li, Xuefeng Kan and Chuansheng Zheng
    Citation: BMC Cancer 2024 24:523
    Content type: Systematic Review Published on:

  49. Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid neoplasm among adults,and approximately 30–40% of patients will experience relapse while 5–10% will suffer from primary refractory disease ca...

    Authors: Marijana Nesic, Mads Sønderkær, Rasmus Froberg Brøndum, Tarec Christoffer El-Galaly, Inge Søkilde Pedersen, Martin Bøgsted and Karen Dybkær
    Citation: BMC Cancer 2021 21:829
    Content type: Research Published on:

Featured videos

View featured videos from across the BMC-series journals

Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us